Last Opportunity for Private Investment (PRE-IPO)
No more surgeries.
ProCore’s Biological Breakthrough
45 minutes of clinic treatment – and a full year of relief. The Israeli technology liberating the world from joint replacements is going public on the Canadian stock exchange.
For details on the investment round ←
Changing the Fate of Joints
Cartilage degeneration is no longer a sentence of suffering or a surgeon’s knife. ProCore has cracked the solution: a unique biological gel (RegenoGel™) injected in a simple procedure, without pain and without prolonged rehabilitation. The result? Immediate return to function and peace of mind for at least 12 months.
Heading toward an IPO on the Canadian stock exchange (TSXV). This is the last entry point before the global breakthrough.
12,000+
Injections successfully performed
$12B
Injection market in 2033
SWISS
Strategic manufacturing agreement
The Vision of Prof. Avner Yayon
The science behind ProCore came from the world’s leading minds (Weizmann Institute, Harvard). This is not just about pain relief, but a biological paradigm shift proving itself anew every day in Israel’s leading clinics.
The company is about to explode on the stock exchange – don’t be left behind.
“It simply works. I returned to a full routine just before the surgeon’s knife touched me.”
Patient (62)
“Doctors are amazed by the immediate results. This is the future of rehabilitative medicine.”
Thought leader in the field
